
CLAIMS

1. A compound having the following Structure (I):



(I)

or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, wherein:

A is phenylene or 5 or 6-membered heteroarylene, each of which is optionally substituted with one or more substituents selected from halo, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, and C_1-C_6 alkoxy;

B is C_3-C_8 monocyclic cycloalkyl, C_6-C_{10} spirocyclic cycloalkyl, C_6-C_{10} fused-multicyclic cycloalkyl, C_6-C_{10} bridged-multicyclic cycloalkyl, 3-8-membered monocyclic heterocyclyl, 3-8-membered monocyclic heterocyclylalkyl, 6-10-membered spirocyclic heterocyclyl, 6-10-membered fused-multicyclic heterocyclyl or 6-10-membered bridged-multicyclic heterocyclyl, each of which is optionally substituted with one or more substituents selected from amino, halo, hydroxyl, oxo, cyano, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxylalkyl, C_1-C_6 aminoalkyl, C_1-C_6 alkylaminylalkyl, C_1-C_6 alkoxy; C_1-C_6 haloalkoxy, C_1-C_6 alkylcarbonyl, C_1-C_6 haloalkylcarbonyl, C_1-C_6 alkylaminyl, C_1-C_6 haloalkylaminyl, C_1-C_6 alkylcarbonylaminyl, C_1-C_6 haloalkylcarbonylaminyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkylcarbonyl, C_3-C_8 halocycloalkylaminyl, and C_3-C_8 cycloalkylcarbonylaminyl;

L is a direct bond, CH_2 or C=O;

R^{1a} and R^{1b} are each independently H, halo, cyano, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy or C_3-C_8 cycloalkyl; and

R^2 is C_1-C_6 alkyl, C_3-C_8 cycloalkyl, 3-8-membered heterocyclyl, 6-10-membered spirocyclic heterocyclyl, 6-10-membered fused-multicyclic heterocyclyl or 6-10-membered bridged-multicyclic heterocyclyl each of which is optionally substituted with one or more substituents selected from halo, cyano, C_1-C_6 alkyl, hydroxyl, alkoxy, and C_1-C_6 haloalkyl.


2. The compound of claim 1, wherein A is unsubstituted phenylene or phenylene substituted with one or more substituents selected from the group consisting of halo, and C_1-C_6 alkoxy.


3. The compound of claim 1, wherein A is a 5 or 6-membered heteroarylene.

4. The compound of claim 1 or 3, wherein A is a pyridinylene or pyrazolylene optionally substituted with one or more substituents selected from halo, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, and C_1-C_6 alkoxy.


5. The compound of any one of claims 1-4, wherein B is unsubstituted or substituted with one or more substituents selected from the group consisting of amino, halo, hydroxyl, oxo, cyano, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxylalkyl, C_1-C_6 aminoalkyl, C_1-C_6 alkylaminylalkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 alkylcarbonyl, C_1-C_6 haloalkylcarbonyl, C_1-C_6 alkylaminyl, C_1-C_6 haloalkylaminyl, C_1-C_6 alkylcarbonylaminyl, C_1-C_6 haloalkylcarbonylaminyl, C_3-C_8 cycloalkylcarbonylaminyl, and C_3-C_8 halocycloalkylaminyl.


6. The compound of any one of claims 1-5, wherein B has one of the following structures:






7. The compound of any one of claims 1-6, wherein B has one of the following structures:







8. The compound of any one of claims 1-7, wherein L is a direct bond.


9. The compound of any one of claims 1-7, wherein L is CH_2.


10. The compound of any one of claims 1-7, wherein L is C=O.


11. The compound of any one of claims 1-10, wherein R^{1a}, R^{1b}, or both are selected from the group consisting of H, methyl, fluoro, chloro, cyano, methoxy, trifluoromethyl, and cyclopropyl.


12. The compound of any one of claims 1-11, wherein R^{1b} is H and R^{1a} is fluoro or chloro, R^{1b} is H and R^{1a} is cyclopropyl, R^{1b} is H and R^{1a} is methyl, R^{1b} is H and R^{1a} is cyano, R^{1b} is H and R^{1a} is H, R^{1b} is H and R^{1a} is methoxy, R^{1b} is H and R^{1a} is trifluoromethyl, R^{1b} is methyl and R^{1a} is fluoro or chloro, or R^{1b} is chloro or fluoro and R^{1a} is fluoro or chloro.


13. The compound of any one of claims 1-12, wherein R^2 is unsubstituted or substituted with one or more substituents selected from the group consisting of methyl, ethyl, iso-propyl, fluoro, trifluoromethyl, and cyano.


14. The compound of any one of claims 1-13, wherein  has one of the following structures:







15. The compound of any one of claims 1-14, wherein  has one of the following structures:











































16. The compound of any one of claims 1-15, wherein the compound has one of the following structures:


































,

,

,

,

,

,

,

,

,

,

,

,

,

,























,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,
























,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,













,















,













,

,









,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,



















































,

,

,

,

,

,

,

,

,

,

,

,






,

,

,

,

,

,

,

,

,

,



,

,

,

, or

, or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof.

17. A pharmaceutical composition comprising the compound of any one of claims 1-16, and a pharmaceutically acceptable carrier, diluent or excipient.

18. Use of a therapeutically effective amount of a compound of any one of claims 1-16, or the pharmaceutical composition of claim 17 in the manufacture of a medicament for treating a LRRK2-mediated disease or disorder in a subject in need thereof.

19. The use of claim 18, wherein the disease or disorder is selected from neurodegenerative diseases, central nervous system (CNS) disorders, cancer, inflammatory diseases, and combinations thereof.

20. The use of claim 19, wherein the neurodegenerative disease is Parkinson's disease, Lewy body dementia, Alzheimer's disease, L-DOPA induced dyskinesia, kidney cancer, breast cancer, prostate cancer, a blood cancer, papillary cancer, lung cancer, acute myelogenous leukemia, multiple myeloma, leprosy, Crohn's disease, amyotrophic lateral sclerosis, rheumatoid arthritis, ankylosing spondylitis, or a combination thereof.